biotech · Atopic Dermatitis · Asthma · APGE
Apogee Therapeutics
Apogee Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- WALTHAM, MA, USA
- Founded
- 2022
- Employees
- 293
- Programs
- 8
- Drugs
- 2
- Patents
- 7
Apogee Therapeutics patents
7 pharmaceutical patents indexed for Apogee Therapeutics. 1 expire within 24 months.
Apogee Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12410137
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
granted -
US 12378231
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
granted -
US 12358979
Antibodies that bind interleukin 13 and methods of use
granted -
US 8685936
Sphingosine kinase inhibitor prodrugs
granted -
US 8557800
Sphingosine kinase inhibitors
granted -
US 8063248
Sphingosine kinase inhibitors
granted -
US 7338961
Sphingosine kinase inhibitors
granted
Frequently asked questions
How many patents does Apogee Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Apogee Therapeutics patents expire?
1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.